Lisa Lupinacci

3.9k total citations
12 papers, 766 citations indexed

About

Lisa Lupinacci is a scholar working on Molecular Biology, Hematology and Epidemiology. According to data from OpenAlex, Lisa Lupinacci has authored 12 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Hematology and 3 papers in Epidemiology. Recurrent topics in Lisa Lupinacci's work include Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (5 papers) and Histone Deacetylase Inhibitors Research (4 papers). Lisa Lupinacci is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (5 papers) and Histone Deacetylase Inhibitors Research (4 papers). Lisa Lupinacci collaborates with scholars based in United States, Taiwan and Greece. Lisa Lupinacci's co-authors include Anthony W. Tolcher, David Olmos, Richard D. Baird, Amita Patnaik, Kyriakos P. Papadopoulos, Johann S. de Bono, Ruth Riisnaes, Lorna Pope, Simon P. Heaton and George Thomas and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Lisa Lupinacci

12 papers receiving 749 citations

Peers

Countries citing papers authored by Lisa Lupinacci

Since Specialization

Citations

This map shows the geographic impact of Lisa Lupinacci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Lupinacci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Lupinacci more than expected).

Fields of papers citing papers by Lisa Lupinacci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Lupinacci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Lupinacci. The network helps show where Lisa Lupinacci may publish in the future.

Co-authorship network of co-authors of Lisa Lupinacci

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Lupinacci. A scholar is included among the top collaborators of Lisa Lupinacci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Lupinacci. Lisa Lupinacci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial 2018 ·Clinical Infectious Diseases ·Chloe Orkin, Kathleen Squires, Jean‐Michel Molina, Paul E. Sax, Wing-Wai Wong, Otto Sussmann, Richard Kaplan, Lisa Lupinacci, Anthony Rodgers, Xia Xu, Gina Lin, Sushma Kumar, Peter Sklar, Bach‐Yen Nguyen, George J. Hanna, Carey Hwang, Elizabeth A. Martin, (unknown)	107
2	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection 2016 ·Gastroenterology ·Paul Y. Kwo, Edward Gane, Cheng‐Yuan Peng, Brian L. Pearlman, John M. Vierling, Lawrence Serfaty, Marı́a Buti, Stephen D. Shafran, Paul Stryszak, Lin Li, Jacqueline Gress, Stuart Black, Frank J. Dutko, Michael Robertson, Janice Wahl, Lisa Lupinacci, Eliav Barr, Barbara Haber	124
3	Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma 2012 ·Clinical Lymphoma Myeloma & Leukemia ·Donna M. Weber, Thorsten Graef, Mohamad A. Hussein, Ronald Sobecks, Gary J. Schiller, Lisa Lupinacci, James S. Hardwick, Sundar Jagannath	37
4	First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors 2011 ·Journal of Clinical Oncology ·Timothy A. Yap, Yan Li, Amita Patnaik, Ivy Fearen, David Olmos, Kyriakos P. Papadopoulos, Richard D. Baird, Liliana Delgado, Adekemi Taylor, Lisa Lupinacci, Ruth Riisnaes, Lorna Pope, Simon P. Heaton, George Thomas, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, Anthony W. Tolcher	433
5	A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. 2011 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Richard D. Baird, Amita Patnaik, Víctor Moreno, Kyriakos P. Papadopoulos, (unknown), David Olmos, (unknown), (unknown), (unknown), (unknown), (unknown), Paul D. Smith, (unknown), (unknown), Lisa Lupinacci, (unknown), Johann S. de Bono	29
6	Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). 2010 ·Journal of Clinical Oncology ·Sundar Jagannath, (unknown), Roman Hájek, Meletios Α. Dimopoulos, (unknown), Sagar Lonial, Thorsten Graef, Lisa Lupinacci, (unknown), K. C. Anderson	1
7	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program 2010 ·Blood ·David S. Siegel, Sundar Jagannath, Roman Hájek, Meletios Α. Dimopoulos, Sung‐Soo Yoon, Sagar Lonial, Jacob P. Laubach, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, (unknown), Kenneth C. Anderson	2
8	Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma. 2009 ·Blood ·David S. Siegel, Sundar Jagannath, Sagar Lonial, Meletios Α. Dimopoulos, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, (unknown), Syed Rizvi, Kenneth C. Anderson	2
9	A248 Vorinostat plus Bortezomib in MM: A Phase I Study 2009 ·Clinical Lymphoma & Myeloma ·(unknown), Sundar Jagannath, Ronald Sobecks, Gary J. Schiller, Lisa Lupinacci, (unknown), (unknown), J. Garcia‐Vargas, Syed Rizvi	2
10	The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma. 2009 ·Blood ·Sundar Jagannath, Donna Weber, Ronald Sobecks, Gary J. Schiller, Lisa Lupinacci, (unknown), Judith E. Allen, Syed Rizvi	3
11	Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women 2008 ·American Journal of Obstetrics and Gynecology ·Eliav Barr, Christine K. Gause, Oliver Bautista, Radha Railkar, Lisa Lupinacci, Ralph P. Insinga, Heather L. Sings, Richard M. Haupt	25
12	Effects of quadrivalent human papillomavirus vaccination – Authors' reply 2007 ·The Lancet ·Kevin A. Ault, (unknown), Richard M. Haupt, Lisa Lupinacci, Emily Barr	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact